Figure 1 Primary cell culture of ovary cancer tumour.

Figure 2 Follow up of cell viability for representative samples 0, 5 and 10 days after seeding.

Figure 3 Representative example of correlation between primary tumour histology and cell culture (morphology and immunophenotype) from an endometrioïd ovarian adenocarcinoma grade 2. Cell culture and, within the box, histology of the tumour are stained by haematoxilin and eosin. Progesterone receptor (PR) immunostaining for ovarian cultured cells and primitive tumour tissue (box) were observed. WT-1 labelings in the cultured cells and primitive tumour tissue (box) are negative. Negative immunostaining for CD163 and calretinin excluded the macrophagic or mesothelial nature of these cells.

Figure 4 Rate of cell death in control and treated cells for patients A, B, C and D. Treated cells were exposed for 72 hours to carboplatin (Carbop.), vepeside (Vep.), topotecan (Topot.) and paclitaxel (Pacl.).

Figure 5 Statistical analyses of cell death rate after treatment with carboplatin, vepeside, topotecan or paclitaxel.

 

Antibody

 

Supplier

 

Clone

 

Dilution

 

Antigen retrieval / Incubation time

Vimentin

DAKO, Glostrup, Denmark

V9

1/200

CC1 mild/20’

WT-1

DAKO

6F-H2

1/50

CC1 standard/32’+ amplif

PR

Ventana, Rocklin, CA, USA

1E2

prediluted

CC1 standard/32’

ER

Ventana

SP1

prediluted

CC1 standard/32’

P53

DAKO

D07

1/50

CC1 standard/32’

P16

Ventana

inK4a

prediluted

CC1 standard/32’

HNF1beta

Atlas Antibodies, Stockholm, Sweden

poly

1/200

CC1 standard/60’+ amplif

CD163

Novocastra, Newcastle upon Tyne, UK

10D6

1/100

CC1 mild/32’

CD68

DAKO, Glostrup, Denmark

PGM1

1/50

CC1 mild/20’

Calretinin

ZYMED, San Francisco, CA

poly

1/100

CC1 mild/32’

Table1 Antibody list and staining procedures.

 

Patient

 

Pathology

Culture success

1

low grade serous adenocarcinoma (type 1)

yes

2

high grade serous adenocarcinoma (type 2) postchemotherapy

Contamination

3

metastatic ductal breast carcinoma

yes

4

endometrioid adenocarcinoma grade 2 FIGO

yes

5

clear cell adenocarcinoma

yes

6

clear cell adenocarcinoma

yes

7

high grade serous adenocarcinoma (type 2)

yes

8

serous borderline cystadenoma

yes

9

high grade serous adenocarcinoma (type 2)

yes

10

high grade serous adenocarcinoma (type 2)

yes

11

high grade serous adenocarcinoma (type 2) postchemotherapy

yes

12

clear cell adenocarcinoma

contamination

13

serous-transitional cell carcinoma

yes

14

endometrioid adenocarcinoma grade 2 FIGO

yes

15

endometrioid adenocarcinoma grade 2 FIGO

yes

16

clear cell adenocarcinoma

yes

17

clear cell adenocarcinoma

yes

18

high grade serous adenocarcinoma (type 2)

yes

19

mature teratoma

yes

20

high grade serous adenocarcinoma (type 2)

yes

21

endometrioid adenocarcinoma grade 2 FIGO

yes

22

endometrioid adenocarcinoma grade 2 FIGO

yes

23

mucinous borderline cystadenoma

yes

24

dysgerminoma

yes

25

high grade serous adenocarcinoma (type 2)

yes

26

high grade serous adenocarcinoma (type 2)

yes

27

high grade serous adenocarcinoma (type 2) postchemotherapy

yes

 

28

high grade serous adenocarcinoma (type 2) and low grade serous adenocarcinoma (type 1)

 

yes

Table2 Histological diagnoses of all 28 samples and successes in culture.

 

Case

 

Diagnosis

 

WT1

 

VIM

 

RE

 

RP

 

P16

 

P53

HNF-
1b

 

8

 

serous borderline cystadenoma

 

+

+
foc

 

+

 

ND

 

ND

 

ND

 

ND

 

10

 

high grade serous adenocarcinoma (type 2)

 

+

+
foc

 

+

 

ND

 

ND

 

ND

 

ND

16

clear cell adenocarcinoma

ND

ND

ND

ND

ND

ND

+

18

high grade serous adenocarcinoma (type 2)

+

-

-

ND

+

-

ND

19

mature teratoma

ND

ND

ND

ND

ND

ND

ND

 

21

 

endometrioid adenocarcinoma grade 2 FIGO

 

-

 

-

 

+

 

+

+
patchy

 

ND

 

-

25

high grade serous adenocarcinoma (type 2)

+

-

-

+

NC

-

ND

 

27

 

high grade serous adenocarcinoma (type 2)
postchemotherapy

 

-

 

-

 

+

 

ND

 

+

 

+

 

ND

 

28

 

high grade serous adenocarcinoma (type 2)
and low grade serous adenocarcinoma (type 1)

 

+
foc

 

-

 

+

 

-

 

-

 

ND

 

-

Table3 List of the 9 interpretable cases. Immunocytochemical features. (ND: not determined)

Patient

Pathology

Proliferation (%)

17

clear cell adenocarcinoma

65,6

21

endometrioid adenocarcinoma grade 2 FIGO

23,7

23

mucinous borderline cystadenoma

21,7

24

dysgerminoma

18,3

25

high grade serous adenocarcinoma (type 2)

16,3

 

27

 

high grade serous adenocarcinoma (type 2)
postchemotherapy

 

19,5

Table4 Percentage of proliferative cells for 6 representative cultures determined by BrdU incorporation.